Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Carbon Dioxide Laser Surgery in Gynecology

  • Author: Janice L Bacon, MD; Chief Editor: Christine Isaacs, MD  more...
 
Updated: Dec 26, 2015
 

History of the Procedure

The key mechanisms of action of the laser were first discovered by Albert Einstein in the early 1900s. Initial results from the use of a carbon dioxide laser for the management of cervical dysplasia were initially less successful than anticipated because of the inability to determine appropriate depth of penetration for prevention of recurrent disease. Not until 1978 did Anderson and Hartley emphasize the actual mechanics for the depth of cervical involvement.[1] Laser technique was further refined and shown to be both practical and efficacious by Jordan in 1985[2] and by Dorsey in 1979,[3]  when the Greater Baltimore Medical Center published the first clinical experience with cervical conizations by carbon dioxide laser. See the image below.

Cervix after laser conization. Cervix after laser conization.

Lasers have provided the laparoscopic surgeon with an efficient method of achieving rapid excision, coagulation, or vaporization of pelvic abnormalities. Most familiar is therapy for pelvic endometriosis or adhesions. When laser is used in combination with other laparoscopic instruments, the variety of procedures performed with the laparoscope may be enhanced.

The carbon dioxide laser has been considered an effective modality for multiple tasks related to the treatment of intraepithelial neoplasia of the lower genital tract, most commonly for large lesions and for multifocal manifestations of human papilloma virus (HPV). The use of this technology is limited in some areas because of healthcare provider training and experience and because of a lack of availability of equipment. Many hospitals require that specific credentials be obtained before using this modality, including documentation of didactic instruction and clinical supervision of initial procedures. 

Next

Problem

Intraepithelial neoplasia is a descriptive histologic term for squamous abnormalities of the vulva (VIN) and perianal area, vagina (VAIN) and cervix (CIN) (see the images below). 

In 2012, the College of American Pathology (CAP) and the American Society for Colposcopy and Cervical Pathology (ASCCP) developed and published the Lower Anogenital Squamous Terminology (LAST) project. This presented the current terminology used to describe Human Papilloma virus associated squamous lesions of the anogenital tract.[4] In the LAST system, histologic cervical findings are described using the same terminology as cytologic findings.

LSIL: low grade squamous intraepithelial lesions - now replaces the designation of CIN I, or mild dysplasia. This category also includes abnormalities previously designated as CIN 2 (moderated dysplasia) which are negative for p16 immunostaining.

HSIL:high grade squamous intraepithelial lesions-represents  abnormalities previously designated CIN 3 (severe dysplasia) and also in cludes prior CIN 2 lesions which are p16 positive, as well as encompassing those cellular abnormalities designated  carcinoma in situ.[4]

The ASCCP published in 2012 updated concensus guidelines for the management of abnormal cervical screening tests, but continues to use the terminology CIN (cervical intraepithelial neoplasia), as delegates to the LAST project determined that the classification of LSIL and HSIL does not yet have enough evidence to allow clear risk-based management guidelines.[5]

White lesion is cervical intraepithelial neoplasm, White lesion is cervical intraepithelial neoplasm, grade I (CIN I).
Cervical intraepithelial neoplasia, grades I and I Cervical intraepithelial neoplasia, grades I and II (CIN I and II).
Vulvar intraepithelial neoplasia, grade I (VIN I). Vulvar intraepithelial neoplasia, grade I (VIN I).

Pelvic pain related to adhesions or endometrial implants also represents a significant disease burden in the United States. Adhesions may be filmy or dense and may involve any pelvic structures. Endometrial implants may be clear or cystic, red or brown/black. Customarily, the older lesions are more darkly colored and accompanied by an increased depth of involvement with contracture of surrounding peritoneum or tissue surfaces. As the severity of endometriosis increases, the presence and severity of adhesions may also increase and become more dense. Visual evaluation of endometriosis may not completely correlate with depth of invasion of implants or with the patient's clinical symptoms.

The precision of the carbon dioxide laser delivered laparoscopically lends itself to intra-abdominal and intrapelvic adhesiolysis or ablation of endometrial implants.

Previous
Next

Epidemiology

Frequency

Acording to the US Centers for Disease Control and Prevention, HPV is so common that almost everyone will be infected at some time in their lives.[6]

In 2005, the US Centers for Disease Control and Prevention estimated that 20 million Americans are DNA positive for anogenital types of human papillomavirus at any time.[7] Almost one half of sexually active adolescents or young adults aged 15-24 years may be infected by the human papillomavirus. In the United States, 6.2 million individuals are estimated to become newly infected with human papillomavirus annually.

Previous
Next

Etiology

The most likely etiology of lower genital tract squamous abnormalities is infection with HPV, a double-stranded DNA virus of the Papovaviridae family. The HPV has more than 100 subtypes and is the major causative factor of malignant and premalignant squamous abnormalities of the anogenital tract.. Serotypes associated with squamous lesions may be designated as having a high or low risk for progression to malignancy. Ultimate cure of the viral infection can only be achieved by the immune system of the human host.

Papillomaviruses are ubiquitous in higher vertebrates. Approximately 40 types of HPV infect the genital tract. Intercellular cytokine-mediated control plays an important role in supression of malignant transformation. A genetic change in pathways controlling intracellular or intercellular signaling may allow propgression to a malignant phenotype.[8]

Treatment modalities, such as the carbon dioxide laser, destroy or excise infected cells, thus reducing the amount of infected tissue and, presumably, the host viral load. The subsequent healing process of the host stimulates viral combat at the surgical site. Patients with abnormal cytology findings or visible lesions must first be evaluated with visual inspection using a colposcope to help determine the location, extent, and severity of the clinical abnormalities. Colposcopically directed biopsies are indicated when dysplasia is present or malignancy is considered, in the clinical opinion of the healthcare provider. Findings from one or more biopsy samples from the involved areas help document the location and histologic severity of the disease.

The carbon dioxide laser has been used for ablating high-grade lesions or excising abnormal areas, including the transformation zone of the cervix. Ablation may frequently be used for treating VIN and is also considered to be a treatment modality for VAIN requiring therapy.

In the pelvis, endometriosis has been hypothesized to be a result of endometrial cells producing disease in areas outside of the uterus, most likely by retrograde menstrual flow via patent fallopian tubes, but also potentially via vascular or lymphatic channels. Altered immune function within the peritoneal cavity, plus other potential factors, then permit development of endometrial implants, most frequently on the ovaries or in the cul-de-sac. Other sites in the abdomen or pelvis or remote sites may become involved.

Within the pelvis, the CO2 laser can be used to ablate affected sites or excise the peritoneum, thus improving anatomic relationships by lysing adhesions and excising endometrial implants.

When used in the pelvis for therapy of adhesions of other etiologies (eg, postoperative or postinfectious), the CO2 laser allows precise incision of the adhesions, restoring local anatomy with a primary goal of reduced, repeat adhesion formation and decreased risk of damage to adjacent structures.

Previous
Next

Indications

The carbon dioxide laser is customarily chosen over other ablative or excisional techniques when great precision is needed, particularly in situations involving large surface areas or when precise control over the depth of penetration is desired. Examples of procedures for which the carbon dioxide laser is indicated include (1) ablation or excision of dysplasia in situations in which minimization of tissue destruction or removal is desired; (2) cervical treatment combined with treatment of dysplasia or condylomata of the vulva, vaginal, perineal, or perirectal areas; (3) multifocal disease of the cervix, vagina, or vulva/perianal areas; (4) ablation or excision of endometrial implants or affected peritoneum; and (5) lysis of intra-abdominal or intrapelvic adhesions.

The carbon dioxide laser is used in conjunction with a laparoscope or colposcope. This allows precise application, which is one advantage of this treatment modality. Another advantage of the laser is hemostasis and minimal thermal necrosis (< 100 µm) when properly set. In addition, the procedure time is brief, and the laser may be used in an office or outpatient setting with the patient under local anesthesia when treating the vulva, vagina, or cervix. The office setting may also be more economical than procedures performed in a surgical suite. Surgical advantages of the intra-abdominal CO2 laser include (1) rapid incision and vaporization, (2) safety and predictability, and (3) lack of contact with the organ.

Patients with abnormal cervical cytology findings must first be evaluated using a colposcope to help determine the location, extent, and severity of the clinical abnormalities. Colposcopically directed biopsies are indicated when the health care provider has determined dysplasia is present. Findings from 1 or more biopsy samples from the involved areas and findings from an endocervical curettage help document the location and histologic severity of the disease present.

The carbon dioxide laser has been used for ablating CIN or excising abnormal areas, including the cervical transformation zone.

Patients with visible lesions of the vagina, grossly compatible with HPV-related disorders, may be inspected with the colposcope and biopsy performed if the provider suspects dysplasia or to exclude malignancy.

Visible lesions of the vulva or perineum and perianal areas may indicate a need for biopsy to evaluate dysplasia, exclude malignancy, or further elucidate dermatologic disorders. The colposcope with or without acetic acid to the vulva may be invaluable in determining the presence or extent of disease while providing focused light in the area of interest.

The CO2 laser may be used whenever a diagnostic laparoscopic procedure can combine a diagnosis of disease and the extent of disease with immediate therapy. It may also be used to augment pain management associated with endometriotic implants via partial excision of the peritoneum or through laser destruction of the medial aspect of the uterosacral ligaments, interrupting nerve endings associated with central pelvic pain.

Previous
Next

Contraindications

Contraindications to using the carbon dioxide laser for the treatment of lower genital tract disease include (1) an inability to visualize the area to be treated because of anatomic considerations (eg, prolapsing lateral vaginal sidewall), (2) preoperative histology findings indicative of malignancy, and (3) inadequate physician training or experience. Laser ablation is contraindicated if the entire lesion is not visible, although excisional procedures may be performed.

Contraindications to laparoscopic use of the CO2 laser include (1) inability to visualize the site to be treated without risk of damage to adjacent structures, (2) anatomic findings not consistent with the diagnosis of endometriosis or adhesions (eg, neoplasm), (3) inadequate physician training or experience.

Previous
 
 
Contributor Information and Disclosures
Author

Janice L Bacon, MD Practicing Physician and Partner, Women’s Health and Diagnostic Center, Lexington Medical Center; Consultant Physician in Contraception, Department of Health and Environmental Control

Janice L Bacon, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, Association of Reproductive Health Professionals, North American Society for Pediatric and Adolescent Gynecology, South Carolina Medical Association, American Society for Colposcopy and Cervical Pathology, American Institute of Ultrasound in Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Christine Isaacs, MD Associate Professor, Department of Obstetrics and Gynecology, Division Head, General Obstetrics and Gynecology, Medical Director of Midwifery Services, Virginia Commonwealth University School of Medicine

Christine Isaacs, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists

Disclosure: Nothing to disclose.

Additional Contributors

Karen Loeb Lifford, MD Director of General Gynecology, Associate Program Director, Department of Obstetrics and Gynecology, Instructor, Brigham and Women's Hospital, Harvard Medical School

Karen Loeb Lifford, MD is a member of the following medical societies: Association of Professors of Gynecology and Obstetrics, Massachusetts Medical Society, Phi Beta Kappa

Disclosure: Nothing to disclose.

References
  1. Anderson MC, Hartley RB. Cervical crypt involvement by intraepithelial neoplasia. Obstet Gynecol. 1980 May. 55(5):546-50. [Medline].

  2. Jordan JA, Woodman CB, Mylotte MJ, et al. The treatment of cervical intraepithelial neoplasia by laser vaporization. Br J Obstet Gynaecol. 1985 Apr. 92(4):394-8. [Medline].

  3. Dorsey JH, Diggs ES. Microsurgical conization of the cervix by carbon dioxide laser. Obstet Gynecol. 1979 Nov. 54(5):565-70. [Medline].

  4. Darragh TM, Colgan TJ, Thomas Cox J, et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 2013 Jan. 32(1):76-115. [Medline].

  5. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. 2012 ASCCP Consensus Guidelines Conference. J Low Genit Tract Dis. 2013 Apr. 17(5 Suppl 1):S1-S27. [Medline].

  6. CDC. Human papillomavirus (HPV): know the facts. Centers for Disease Contol and Prevention. September 30, 2015. Available at http://www.cdc.gov/hpv/hcp/know-facts.html. Accessed: November 5, 2015.

  7. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM, ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007 Jun 1. 195(11):1582-9. [Medline]. [Full Text].

  8. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000 May 3. 92(9):690-8. [Medline].

  9. McCrory DC, Matchar DB, Bastian L, et al. Evaluation of cervical cytology. Evid Rep Technol Assess (Summ). 1999 Jan. 1-6. [Medline].

  10. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. Proyecto Epidemiologico Guanacaste Group. J Natl Cancer Inst. 2008 Apr 2. 100(7):513-7. [Medline].

  11. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep. 189(1):12-9. [Medline].

  12. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010 Nov. 11(11):1048-56. [Medline].

  13. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6. 348(6):518-27. [Medline].

  14. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003 Jan 1. 95(1):46-52. [Medline].

  15. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008 Oct 13. 337:a1754. [Medline].

  16. Schiffman M, Glass AG, Wentzensen N, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev. 2011 Jul. 20(7):1398-409. [Medline].

  17. Gajjar K, Martin-Hirsch PP, Bryant A. Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment. Cochrane Database Syst Rev. 2012 Oct 17. 10:CD006120. [Medline].

  18. Vanichtantikul A, Charoenkwan K. Lidocaine spray compared with submucosal injection for reducing pain during loop electrosurgical excision procedure: a randomized controlled trial. Obstet Gynecol. 2013 Sep. 122(3):553-7. [Medline].

  19. Wisniewski PM, Warhol MJ, Rando RF, Sedlacek TV, Kemp JE, Fisher JC. Studies on the transmission of viral disease via the CO2 laser plume and ejecta. J Reprod Med. 1990 Dec. 35(12):1117-23. [Medline].

  20. Bellina JH, Stjernholm RL, Kurpel JE. Analysis of plume emissions after papovavirus irradiation with the carbon dioxide laser. J Reprod Med. 1982 May. 27(5):268-70. [Medline].

  21. OSHA. Laser/Electrosurgery Plume. United States Department of Labor, Occupational Safety & Health Administration. Available at http://www.osha.gov/SLTC/laserelectrosurgeryplume/index.html. Accessed: March 10, 2009.

  22. Dorsey JH. Laser surgery for cervical intraepithelial neoplasia. Chohan N, Barron HA, eds. Obstetrics and Gynecology Clinics of North America. Philadelphia, Pa: WB Saunders Company; 1991. 475-489.

  23. Reid R. Physical and surgical principles of laser surgery in the lower genital tract. Chohan N, Barron HA, eds. Obstetrics and Gynecology Clinics of North America. Philadelphia, Pa: WB Saunders and Company; 1991. 429-74.

  24. Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol. 1998 Nov. 92(5):737-44. [Medline].

  25. Gardeil F, Barry-Walsh C, Prendiville W, Clinch J, Turner MJ. Persistent intraepithelial neoplasia after excision for cervical intraepithelial neoplasia grade III. Obstet Gynecol. 1997 Mar. 89(3):419-22. [Medline].

  26. Andersen ES, Nielsen K. Adenocarcinoma in situ of the cervix: a prospective study of conization as definitive treatment. Gynecol Oncol. 2002 Sep. 86(3):365-9. [Medline].

  27. Mathevet P, Dargent D, Roy M, Beau G. A randomized prospective study comparing three techniques of conization: cold knife, laser, and LEEP. Gynecol Oncol. 1994 Aug. 54(2):175-9. [Medline].

  28. Spitzer M. Vaginal estrogen administration to prevent cervical os obliteration following cervical conization in women with amenorrhea. J Low Genit Tract Dis. 1997 Apr. 1(2):53-6. [Medline].

  29. Sadler L, Saftlas A. Cervical surgery and preterm birth. J Perinat Med. 2007. 35(1):5-9. [Medline].

  30. Sjoborg KD, Vistad I, Myhr SS, et al. Pregnancy outcome after cervical cone excision: a case-control study. Acta Obstet Gynecol Scand. 2007. 86(4):423-8. [Medline].

  31. Jancar N, Rakar S, Poljak M, Fujs K, Kocjan BJ, Vrtacnik-Bokal E. Efficiency of three surgical procedures in eliminating high-risk human papillomavirus infection in women with precancerous cervical lesions. Eur J Gynaecol Oncol. 2006. 27(3):239-42. [Medline].

  32. Kjellberg L, Wadell G, Bergman F, et al. Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. Am J Obstet Gynecol. 2000 Nov. 183(5):1238-42. [Medline].

  33. Solomon D, Schiffman M, Tarone R, et al. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001 Feb 21. 93(4):293-9. [Medline].

  34. Bar-Am A, Daniel Y, Ron IG, et al. Combined colposcopy, loop conization, and laser vaporization reduces recurrent abnormal cytology and residual disease in cervial dysplasia. Gynecol Oncol. 2000. 78:47-51. [Medline].

  35. dos Santos L, Odunsi K, Lele S. Clinicopathologic outcomes of laser conization for high-grade cervical dysplasia. Eur J Gynaecol Oncol. 2004. 25(3):305-7. [Medline].

  36. Klobucar A, Hrgovic Z, Bukovic D, et al. The treatment of cervical dysplasia with laser. Med Arh. 2004. 58(6):355-7. [Medline].

  37. Mitchell MF, Tortolero-Luna G, Wright T, et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J Natl Cancer Inst Monogr. 1996. (21):17-25. [Medline].

  38. Ueda M, Ueki K, Kanemura M, et al. Diagnostic and therapeutic laser conization for cervical intraepithelial neoplasia. Gynecol Oncol. 2006 Apr. 101(1):143-6. [Medline].

  39. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005 Mar 1. 191(5):731-8. [Medline].

  40. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012 May-Jun. 62(3):147-72. [Medline]. [Full Text].

  41. Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007 Oct. 11(4):201-22. [Medline].

  42. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology. Obstet Gynecol. 2008 Dec. 112(6):1419-44. [Medline].

  43. Choussein S, Srouji SS, Farland LV, Gargiulo AR. Flexible carbon dioxide laser fiber versus ultrasonic scalpel in robot-assisted laparoscopic myomectomy. J Minim Invasive Gynecol. 2015 Nov-Dec. 22(7):1183-90. [Medline].

  44. Yoon BS, Seong SJ, Song T, Kim ML, Kim MK. Risk factors for treatment failure of CO2 laser vaporization in cervical intraepithelial neoplasia 2. Arch Gynecol Obstet. 2014 Jul. 290(1):115-9. [Medline].

 
Previous
Next
 
White lesion is cervical intraepithelial neoplasm, grade I (CIN I).
Cervical intraepithelial neoplasia, grades I and II (CIN I and II).
Cervix after laser conization.
Vulvar intraepithelial neoplasia, grade I (VIN I).
Table. The 4 Surgical Planes in Laser Surgery of the Vulva*
Parameter First Second Third Fourth
Tissue Surface epithelium Dermal papillae Pilosebaceous ducts Pilosebaceous glands
Vaporization zone Proliferating layer of epidermis Papillary dermis (superficial) Upper reticular dermis Mid-reticular dermis
Necrosis Zone Basement membrane Deep papillary dermis Midreticular dermis Deep reticular dermis
Healing Rapid/nonscarring Rapid/nonscarring Slower/usually nonscarring Skin grafting required
Landmarks visualized Pink surface after removing char Yellow, nonreflective White, fibrous arcuate vessels seen Skin appendages visible
*Adapted from Obstetrics and Gynecology Clinics of North America, Lasers in Gynecology[23]
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.